Mitral Valve Prolapse: Symptoms, Risks, and Management

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on genetics and peptide-related health. Browse all Peptides & GLP-1 education

Mitral valve prolapse (MVP) happens when the two flaps of the mitral valve bulge back into the left atrium as the heart contracts. It is one of the most common valve conditions, and while most people with MVP live normal lives, a subset develop valve leakage that needs monitoring. Genetics plays a clear role in the inherited forms.

What Mitral Valve Prolapse Is

The mitral valve sits between the left atrium and left ventricle and keeps blood moving in one direction. In MVP, the valve tissue is often thickened or overly stretchy — a change called myxomatous degeneration — so the flaps do not close tightly. When this allows blood to leak backward, it is called mitral regurgitation.

MVP is common, affecting an estimated 2 to 3 percent of adults, and it can run in families. The degree of prolapse ranges widely: some valves barely bulge and never leak, while others degenerate enough over decades to strain the heart. That variability is exactly why individual context — including inherited tissue biology — matters.

Symptoms and How It Is Found

Many people with MVP have no symptoms and learn about it only when a clinician hears a characteristic click or murmur. When symptoms do appear, they can include palpitations, a fluttering heartbeat, chest discomfort, lightheadedness, or fatigue. An echocardiogram confirms the diagnosis and measures how much, if any, leakage is present.

Genes Linked to Mitral Valve Prolapse

Familial MVP has been traced to specific named genes. The FLNA gene, which encodes filamin A, causes an X-linked form of myxomatous valve disease and was one of the first MVP genes identified. The DCHS1 gene, part of the cell-adhesion machinery that guides valve development, carries variants strongly associated with non-syndromic MVP in family and population studies.

Additional loci such as DZIP1 have been linked through genome-wide research. Connective-tissue disorders driven by genes like FBN1 (Marfan syndrome) also raise MVP risk, which is why valve findings sometimes prompt a broader genetic and clinical review. These genes influence how valve tissue is built and maintained over time.

Risks and Possible Complications

Most MVP is benign. The risks that clinicians watch for are progressive mitral regurgitation, which can strain the heart over years, and less commonly arrhythmias. Significant leakage may eventually require surgical repair. Regular follow-up with echocardiography is how providers track whether a stable valve is staying stable.

How MVP Is Monitored and Managed

Management is individualized and directed by a cardiologist. For mild MVP without leakage, periodic monitoring is often all that is recommended. When regurgitation is significant, treatment decisions — including whether and when to consider valve repair — are made clinically based on imaging and symptoms. Genetic insight can add family-history context but does not replace this evaluation.

What Genetic Insight Adds

Genetics is a guide, not a guarantee. Understanding whether connective-tissue and cardiovascular pathways run in your family gives useful background before a clinical work-up. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across pathways tied to tissue structure and cardiovascular biology, helping you bring informed context to your provider. PlexusDx tells you about your biology — it does not tell you what to put in your body.

Frequently Asked Questions

Is mitral valve prolapse hereditary?

MVP can be hereditary. Familial forms are linked to named genes including FLNA, DCHS1, and DZIP1, and connective-tissue conditions tied to FBN1 raise risk. Many cases, however, appear without a clear family history, so genetics is one contributing factor among several.

Can genetic testing diagnose mitral valve prolapse?

No. Only an echocardiogram can diagnose MVP by imaging the valve directly. Genetic testing offers pathway-level context about inherited tissue and cardiovascular tendencies, which may inform a family discussion, but it cannot confirm or rule out the condition on its own.

Is mitral valve prolapse dangerous?

For most people, MVP is not dangerous and requires only occasional monitoring. The main concern is significant mitral regurgitation, which can develop over years and may eventually need repair. Regular cardiology follow-up is how providers catch meaningful changes early.

What lifestyle steps help with MVP?

Lifestyle steps are supportive, not curative, and should be reviewed with your cardiologist. Staying active, managing caffeine and stimulants if they trigger palpitations, staying hydrated, and keeping scheduled echocardiograms are common, evidence-informed habits for people living with mitral valve prolapse.

Curious how your inherited biology connects to cardiovascular pathways? Explore the Precision Peptide Genetic Test.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.